RNA-seq of human near-haploid cell line HAP1 with CRISPR-edited frameshift mutations

HAP-1, K562

erythrocyte, fibroblast

chronic myelogenous leukemia

104bp insertion in exon 5, 1bp insertion in exon 5, 20bp deletion in exon 4, 5bp deletion in exon 6

ATAD2 CRISPR/Cas9 mediated frameshift mutation, BAZ2A CRISPR/Cas9 mediated frameshift mutation, BLVRB CRISPR/Cas9 mediated frameshift mutation, BRD2 CRISPR/Cas9 mediated frameshift mutation, BRD3 CRISPR/Cas9 mediated frameshift mutation, BRD4 CRISPR/Cas9 mediated frameshift mutation, BRD9 CRISPR/Cas9 mediated frameshift mutation, DNMT1 CRISPR/Cas9 mediated frameshift mutation, EIF2AK3 CRISPR/Cas9 mediated frameshift mutation, EP300 CRISPR/Cas9 mediated frameshift mutation, HDAC1 CRISPR/Cas9 mediated frameshift mutation, KDM1A CRISPR/Cas9 mediated frameshift mutation, MTF2 CRISPR/Cas9 mediated frameshift mutation, NGLY1 CRISPR/Cas9 mediated frameshift mutation, PI4KB CRISPR/Cas9 mediated frameshift mutation, RIPK1 CRISPR/Cas9 mediated frameshift mutation, RIPK2 CRISPR/Cas9 mediated frameshift mutation, UCHL1 CRISPR/Cas9 mediated frameshift mutation, wild type genotype

Homo sapiens

bone marrow

ATAD2 homozygous knockout, BAZ2A homozygous knockout, BLVRB homozygous knockout, BRD2 homozygous knockout, BRD3 homozygous knockout, BRD4 homozygous knockout, BRD9 homozygous knockout, DNMT1 homozygous knockout, EIF2AK3 homozygous knockout, EP300 homozygous knockout, HDAC1 homozygous knockout, KDM1A homozygous knockout, MTF2 homozygous knockout, NGLY1 heterozygous knockout, PI4KB homozygous knockout, RIPK1 homozygous knockout, RIPK2 homozygous knockout, UCHL1 homozygous knockout, wild type